BSF Enterprise PLC (BSFA) AI Stock Analysis

• Market Cap: £2.50M
• Dividend Yield: N/A
• Average Volume (3M): 190.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: -64.18%
• EPS Growth: 12.05%
• Country: UK
• Employees: 15
• Sector: Healthcare
• Sector Strength: 37
• Industry: Asset Management
• EPS (TTM): >-0.01
• Shares Outstanding: 123,648,440
• 10 Day Avg. Volume: 215,354
• 30 Day Avg. Volume: 190,866
• PEG Ratio: -0.51
• Price to Book (P/B): 0.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £2.50
• Price Target Upside: 23.76% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: 2.00p ▼(-0.99%Downside)

BSF Enterprise PLC's overall stock score is primarily influenced by positive corporate developments, which show promise for future growth. However, the score is tempered by negative financial performance and technical indicators, along with a poor valuation due to unprofitability. The company's strategic moves, especially in sustainable and innovative biotechnology, are promising but need to translate into improved financial metrics to boost the overall score.

BSF Enterprise PLC Business Overview & Revenue Model

Company Description

BSF Enterprise Plc does not have significant operations. It intends to acquire the companies or businesses within marketing and technology sectors. The company was incorporated in 2018 and is based in London, United Kingdom.

How the Company Makes Money

BSF Enterprise PLC generates revenue through the commercialization of its proprietary tissue engineering technologies and biomaterials. The company earns money by licensing its technologies to pharmaceutical and biotechnology companies, as well as through direct sales of its lab-grown tissues and biomaterials to research institutions and industrial clients. Strategic partnerships with leading companies in the healthcare and biotechnology sectors also play a significant role in supporting its earnings. Additionally, BSF Enterprise may receive grants and funding from governmental and non-governmental organizations to support its research and development efforts.

BSF Enterprise PLC Financial Statement Overview

Summary

The company shows strong revenue growth but is hindered by significant operational losses and negative cash flows. A strong equity position is a positive aspect, but declining stockholders' equity and the presence of debt present financial risks.

Income Statement

The company has shown a significant increase in revenue from previous years, indicating growth. However, the gross profit is negative, with substantial losses at the EBIT and net income levels, reflecting continued operational challenges and unprofitability.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, indicating financial stability. However, the presence of debt and declining stockholders' equity over the years are potential risks.

Cash Flow

The cash flow statement reveals negative operating cash flow, which is concerning. Free cash flow remains negative, though capital expenditures are minimal. The company's operating activities are not generating sufficient cash to cover its losses.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	57.82K	12.94K	0.00	0.00	0.00
Gross Profit	-26.64K	-86.55K	-160.50K	0.00	0.00
EBITDA	-1.68M	-1.46M	-905.76K	-58.22K	0.00
Net Income	-1.67M	-1.50M	-930.04K	-58.43K	-93.93K
Balance Sheet
Total Assets	3.50M	5.26M	4.03M	401.45K	455.40K
Cash, Cash Equivalents and Short-Term Investments	637.66K	2.32M	1.06M	359.87K	445.06K
Total Debt	78.05K	156.93K	231.88K	0.00	0.00
Total Liabilities	305.07K	401.63K	449.47K	36.63K	32.26K
Stockholders Equity	3.19M	4.86M	3.58M	364.82K	423.14K
Cash Flow
Free Cash Flow	-1.60M	-1.44M	-677.86K	-85.19K	-107.14K
Operating Cash Flow	-1.59M	-1.38M	-667.24K	-85.19K	-107.14K
Investing Cash Flow	-12.02K	-64.85K	1.75K	0.00	0.00
Financing Cash Flow	-78.88K	2.70M	1.37M	0.00	0.00

BSF Enterprise PLC Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BSFA, the sentiment is Neutral. The current price of 2.02 is above the 20-day moving average (MA) of 1.97, below the 50-day MA of 2.12, and below the 200-day MA of 2.46, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.69 is Neutral, neither overbought nor oversold. The STOCH value of 54.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:BSFA.

BSF Enterprise PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSFA	52 Neutral	£2.50M	―	-46.41%	―	-64.18%	12.05%
Sector *	51 Neutral	$7.30B	0.27	-62.71%	2.44%	15.02%	0.60%
BLU	―	£8.08M	―	-140.34%	―	―	―
GUN	47 Neutral	£1.57M	―	-34.06%	―	―	80.00%
BRH	43 Neutral	£1.73M	―	-38.03%	―	502.47%	-501.58%
PRIM	―	£5.44M	2.04	48.96%	―	―	―
CHP	44 Neutral	£2.28M	―	-71.01%	―	―	―

BSF Enterprise PLC Corporate Events

BSF Enterprise’s Kerato Secures Global Rights for Innovative Corneal Treatment

BSF Enterprise PLC’s subsidiary, Kerato Limited, has signed an exclusive worldwide option agreement with Université de Montréal for the intellectual property of LiQD Cornea, a novel treatment for corneal damage. This agreement strengthens Kerato’s IP portfolio in corneal tissue engineering and supports the development of scalable alternatives to donor cornea transplantation, addressing the global demand for corneal transplants. With over 13 million people waiting for corneal transplants and a market expected to reach USD 1.86 billion by 2033, this agreement is a pivotal step in Kerato’s commercialization strategy. The agreement facilitates regulatory preparations and clinical trials, enhancing Kerato’s position in the market and attracting potential non-dilutive investments.

BSF Enterprise PLC Reports Reduced Losses and Advances in Lab-Grown Leather

BSF Enterprise PLC announced its unaudited interim results for the six months ending March 31, 2025, reporting a reduced net loss due to lower administrative expenses and increased grant income. The company has made significant strides in its business operations, including a strategic partnership with Sartorius to advance lab-grown leather production, and the development of innovative products like Elemental X™, a leather alternative inspired by T-Rex DNA. These advancements have attracted global media attention and interest from major fashion brands, positioning BSF for future growth and innovation in sustainable biotechnology.

BSF Enterprise PLC Amends Warrant Terms to Boost Investment Appeal

BSF Enterprise PLC has announced an amendment to its warrant instrument, originally issued on 26 April 2022. The exercise price for the warrants has been reduced from 15p to 7.5p, and the exercise term has been extended by two years, now expiring on 17 May 2027. This adjustment aims to enhance the attractiveness of the warrants, potentially increasing stakeholder engagement and investment in the company’s innovative tissue-engineered materials.

BSF Enterprise’s Lab-Grown Leather Ltd Makes Breakthroughs in Sustainable Leather

BSF Enterprise PLC’s subsidiary, Lab-Grown Leather Ltd (LGL), has announced significant advancements in its lab-grown leather products, specifically with its Elemental+™ and Elemental X™ lines. Elemental+™ offers ultra-thin and strong leather, ideal for industries where weight is critical, while Elemental X™ includes the innovative T-Rex leather, derived from synthetic T-Rex DNA, which has attracted global media attention and new commercial partnerships. These developments position LGL as a leader in sustainable leather alternatives, with implications for luxury goods, aerospace, and automotive markets.